Ann: Change of Director's Interest Notice, page-14

There were essentially 2 ways things could have gone in the past 2 years. The way they did and the way they did with Nuvaring being approved in 2019. I don't think everyone would have been so critical if Nuvaring had been approved in 2019. The generics issue would have still been there but Nuvaring would have smoothed things out a lot. I don't think you can blame Mayne for Nuvaring. Mithra got it approved in several other markets and the FDA knock back really seems to have been a left field thing. In 2019, on the balance of probabilities of approval or not approval, the odds would have been on approval. It just didn't happen. But back to the future. If gNuvaring is approved shortly, Mayne will have had 2 big guns products approved in 6 months. Let's see how it goes but I'm confident.